Cargando…

Adjuvant treatment in biliary tract cancer

Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with a dismal prognosis. Despite radical surgery, the five-year overall survival (OS) does not exceed 40% in the best series. Adjuvant treatments are widely used even though they have mainly been investigated in small retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palloni, Andrea, Frega, Giorgio, De Lorenzo, Stefania, Rizzo, Alessandro, Abbati, Francesca, Deserti, Marzia, Tavolari, Simona, Brandi, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798763/ https://www.ncbi.nlm.nih.gov/pubmed/35117108 http://dx.doi.org/10.21037/tcr.2018.08.17

Ejemplares similares

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster
por: Brandi, Giovanni, et al.
Publicado: (2020)

Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study
por: Vasuri, Francesco, et al.
Publicado: (2023)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
por: Di Federico, Alessandro, et al.
Publicado: (2022)

In Reply
por: Brandi, Giovanni, et al.
Publicado: (2016)

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?
por: Brandi, Giovanni, et al.
Publicado: (2020)

Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
por: Deiana, Chiara, et al.
Publicado: (2023)

Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
por: Brandi, Giovanni, et al.
Publicado: (2018)

Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
por: De Lorenzo, Stefania, et al.
Publicado: (2018)

The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
por: Palloni, Andrea, et al.
Publicado: (2023)

Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements
por: Frega, Giorgio, et al.
Publicado: (2020)

IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?
por: Brandi, Giovanni, et al.
Publicado: (2022)

Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer
por: Garajová, Ingrid, et al.
Publicado: (2017)

Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations
por: Brandi, Giovanni, et al.
Publicado: (2012)

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
por: Carloni, Riccardo, et al.
Publicado: (2023)

Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
por: Rizzo, Alessandro, et al.
Publicado: (2022)

The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments
por: Brandi, Giovanni, et al.
Publicado: (2019)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review
por: Tavolari, Simona, et al.
Publicado: (2023)

The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation
por: Ravaioli, Matteo, et al.
Publicado: (2017)

Adjuvant therapy of biliary tract cancers
por: Kefas, Joanna, et al.
Publicado: (2023)

Evolution of the Experimental Models of Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2020)

Bile cell‑free DNA: a game changer for management of biliary tract cancer?
por: Rizzo, A., et al.
Publicado: (2022)

Adjuvant Radio-chemotherapy for extrahepatic biliary tract cancers
por: Bonet Beltrán, Marta, et al.
Publicado: (2011)

Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link
por: Brandi, Giovanni, et al.
Publicado: (2022)

Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
por: Brandi, Giovanni, et al.
Publicado: (2015)

Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers
por: Conci, Simone, et al.
Publicado: (2023)

Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
por: Frega, Giorgio, et al.
Publicado: (2023)

Adjuvant treatments for biliary atresia
por: Burns, Jessica, et al.
Publicado: (2020)

Mutational spectrum for guiding the decision of adjuvant treatment in patients with resected biliary tract carcinoma
por: Li, Yunfeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3vrn0ea092l1lio31a3gbdqfoi